Budipine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Budipine
Budipine.svg
Systematic (IUPAC) name
1-tert-butyl-4,4-diphenylpiperidine[1]
Clinical data
AHFS/Drugs.com International Drug Names
Identifiers
CAS Number 57982-78-2 YesY
ATC code N04BX03
PubChem CID 68778
ChemSpider 62021 YesY
UNII L9026OPI2Z YesY
KEGG D07306 YesY
ChEMBL CHEMBL334491 YesY
Chemical data
Formula C21H27N
Molar mass 293.446 g/mol
  (verify)

Budipine (brand name Parkinsan) is an antiparkinson agent marketed for the treatment of Parkinson's disease.[2][3][1]

While its exact mechanism of action is not well characterized,[2] it is believed to be an NMDA receptor antagonist,[4][5] but also promoting the synthesis of dopamine.[6]

Because it provides additional benefits relative to existing treatments, it probably does not precisely mimic the mechanism of an existing known treatment.[6][7]

See also[edit]

References[edit]

  1. ^ Martndale: The Complete Drug Reference, 35th Ed.
  2. ^ a b Heinz Reichmann (October 2006). "Budipine in Parkinson's tremor.". Journal of the Neurological Sciences 248 (1-2): 53–55. doi:10.1016/j.jns.2006.05.039. PMID 16784759. 
  3. ^ H. Przuntek, T. Müller (1999). "Clinical efficacy of budipine in Parkinson's disease.". Journal of Neural Transmission. Supplementa 56: 75–82. doi:10.1007/978-3-7091-6360-3_3. PMID 10370903. 
  4. ^ J. Kornhuber, B. Herr, J. Thome, P. Riederer. "The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue". J.Neural Transm.Suppl. 46:127-133, 1995. PMID 8821048
  5. ^ Gene C. Palmer (September 2001). "Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies.". Current Drug Targets 2 (3): 241–271. doi:10.2174/1389450013348335. PMID 11554551. 
  6. ^ a b Przuntek H, Bittkau S, Bliesath H; et al. (May 2002). "Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen". Arch. Neurol. 59 (5): 803–6. doi:10.1001/archneur.59.5.803. PMID 12020263. 
  7. ^ Jenny C.E. Owen, Peter S. Whitton (October 2006). "Effects of amantadine and budipine on antidepressant drug-evoked changes in extracellular dopamine in the frontal cortex of freely moving rats.". Brain Research 1117 (1): 206–212. doi:10.1016/j.brainres.2006.07.039. PMID 16996043.